Two Sigma Advisers’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Two Sigma Advisers’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,600	Closed	-$377K	–	2827
2022 Q4	$377K	Sell	18,600 -4,800	-21%	-$73.6K	﹤0.01%	1989
2022 Q3	$252K	Sell	23,400 -51,000	-69%	-$578K	﹤0.01%	2128
2022 Q2	$892K	Buy	74,400 +1,700	+2%	+$27.4K	﹤0.01%	1650
2022 Q1	$1.56M	Sell	72,700 -9,700	-12%	-$257K	﹤0.01%	1395
2021 Q4	$2.77M	Sell	82,400 -700	-0.8%	-$19.5K	0.01%	1028
2021 Q3	$2.14M	Buy	+83,100	New	+$1.49M	0.01%	1212

Two Sigma Advisers's OPNT Position: Q1 2023 in Review

Two Sigma Advisers sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 18,600 shares — an estimated $377K sold.

Two Sigma Advisers first reported a position in OPNT in Q3 2021 and held it in 6 quarters. The position peaked at $2.77M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Two Sigma Advisers reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Two Sigma Advisers sold 18,600 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $377K.
Two Sigma Advisers first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Two Sigma Advisers's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $2.77M in Q4 2021.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.